sensit
specif
immunofluoresc
assay
enzym
immunoassay
detect
antibodi
specif
sever
acut
respiratori
syndrom
coronaviru
sarscov
compar
laboratoryconfirm
sar
case
appear
persist
sarscovspecif
antibodi
assess
immunoglobulin
g
detect
sampl
collect
within
day
persist
day
onset
ill
sever
acut
respiratori
syndrom
sar
new
diseas
probabl
case
report
world
health
organ
august
case
occur
china
case
largest
outbreak
beij
case
taiwan
hong
kong
singapor
canada
http
serolog
evid
sar
coronaviru
sarscov
infect
found
patient
symptom
fit
clinic
definit
sar
although
data
perform
variou
antibodi
detect
assay
persist
sarscovspecif
antibodi
lack
first
aim
studi
compar
sensit
specif
commerci
immunofluoresc
assay
ifa
euroimmun
ag
germani
recombin
doublenucleocapsid
antigen
sandwich
enzymelink
immunosorb
assay
elisa
wantai
biolog
pharmaci
enterpris
compani
ltd
beij
china
sarscovspecif
immunoglobulin
g
igg
igm
patient
sarscov
rna
detect
revers
transcriptas
pcr
rtpcr
second
aim
assess
time
appear
persist
sarscovspecif
antibodi
onset
diseas
three
hundr
four
patient
fit
sar
clinic
case
definit
fever
higher
cough
short
breath
new
pulmonari
infiltr
chest
radiographi
close
contact
person
suspect
probabl
case
hospit
ditan
hospit
beij
china
march
may
probabl
case
regard
laboratori
confirm
sarscovspecif
igg
andor
igm
detect
ifa
within
week
onset
ill
andor
sarscov
rna
detect
rtpcr
within
week
sarscov
infect
laboratori
confirm
case
individu
test
sarscov
neg
altern
laboratori
diagnos
mean
age
individu
laboratoryconfirm
case
year
includ
health
care
worker
patient
signific
underli
ill
sar
acquisit
hospit
set
either
health
care
worker
inpati
hospit
visitor
occur
case
individu
acquir
sar
follow
exposur
home
famili
member
friend
hospitalacquir
infect
clinic
featur
similar
report
elsewher
data
shown
comparison
ifa
elisa
detect
sarscovspecif
igg
igm
test
perform
patient
sarscov
detect
respiratori
fecal
sampl
rtpcr
sarscov
igm
detect
peopl
sarscov
igg
detect
peopl
ifa
igm
detect
peopl
igg
detect
peopl
elisa
control
includ
asymptomat
close
contact
individu
sar
case
medic
worker
individu
chronic
hepat
b
case
hepat
c
case
human
immunodefici
viru
type
case
control
found
sarscov
antibodi
ifa
sarscov
igm
detect
one
person
hepat
b
hepat
c
group
igg
detect
two
human
immunodefici
virusinfect
individu
elisa
therefor
overal
sensit
specif
sarscov
igg
detect
ifa
rtpcrposit
patient
compar
respect
elisa
posit
predict
valu
ppv
ifa
elisa
igg
detect
neg
predict
valu
npv
respect
sensit
specif
sarscovspecif
igm
detect
ifa
respect
compar
respect
elisa
igm
detect
ppv
ifa
elisa
igm
detect
respect
npv
respect
one
hundr
eighteen
patient
sarscovspecif
igg
detect
ifa
elisa
ifa
posit
elisa
neg
ifa
neg
elisa
posit
neg
assay
appear
persist
sarscovspecif
antibodi
diseas
onset
serial
serum
sampl
total
number
sampl
per
patient
sar
patient
collect
date
time
diseas
onset
avail
test
sarscovspecif
igm
igg
ifa
tabl
sampl
collect
first
day
ill
sarscov
igg
detect
sarscov
igm
detect
level
detect
increas
second
day
sampl
seroposit
sarscov
igg
seroposit
igm
serum
sampl
collect
day
diseas
onset
sarscov
igg
seroposit
sarscovspecif
igm
level
drop
earli
week
onset
ill
data
shown
agreement
publish
data
examin
antibodi
persist
hospit
discharg
sampl
patient
collect
day
onset
ill
test
presenc
sarscovspecif
igg
igm
iga
ifa
sarscov
igg
detect
show
titer
sarscov
igm
detect
iga
detect
sinc
clinic
case
definit
sar
similar
sever
atyp
pneumonia
laboratori
test
accur
diagnos
sarscov
infect
import
sarscov
rtpcr
modest
sensit
approxim
singl
respiratori
sampl
collect
earli
ill
although
sensit
improv
serial
sampl
collect
first
week
sinc
maxim
viral
shed
occur
day
onset
reliabl
laboratori
test
confirm
sar
detect
sarscovspecif
antibodi
hong
kong
prospect
studi
sar
case
demonstr
sarscov
igg
seroconvers
case
use
inhous
indirect
ifa
acetonefix
sarscovinfect
vero
cell
antibodi
detect
mean
day
rang
onset
level
detect
similar
group
retrospect
analysi
case
patient
acuteand
convalescentphas
sera
demonstr
seroconvers
fourfold
rise
sarscovspecif
antibodi
level
ifa
control
sera
neg
sarscovspecif
antibodi
detect
ifa
sar
case
combin
seri
seroconvers
usual
occur
day
ifa
antibodi
detect
earlier
ifa
elisa
number
inhous
elisa
format
develop
sarscov
antibodi
detect
although
publish
data
compar
sensit
specif
elisa
ifa
antibodi
detect
system
western
blot
neutral
limit
elisa
antigen
use
deterg
extract
gamma
irradi
sarscovinfect
vero
cell
abl
detect
seroconvers
antibodi
rise
limit
studi
sar
patient
differ
countri
antibodi
detect
week
onset
gener
elisa
titer
higher
ifa
titer
sarscov
antibodi
detect
sera
blood
donor
peopl
infect
human
coronaviru
import
inhous
commerci
elisa
valid
standard
clinic
case
definit
rtpcr
result
confirm
sinc
interpret
serosurvey
may
difficult
shown
patient
singl
institut
fit
sar
clinic
case
definit
laboratori
confirm
sarscov
infect
sensit
specif
sarscov
igg
assay
either
commerci
ifa
recombin
nucleocapsid
antigen
elisa
high
context
sar
outbreak
inspir
confid
use
sar
recur
importantli
sensit
specif
antibodi
assay
studi
gener
sarscov
rtpcrposit
case
rather
case
identifi
clinic
definit
sar
etiolog
agent
may
present
interest
fact
sarscovspecif
antibodi
found
asymptomat
health
care
worker
came
close
contact
sar
patient
sarscov
igg
antibodi
detect
ifa
appear
earli
ill
antibodi
sometim
found
within
first
week
day
ill
sampl
posit
confirm
find
studi
show
diagnost
util
serolog
sar
investig
persist
sarscov
antibodi
unknown
import
interpret
result
sar
reexposur
occur
complet
seroepidemiolog
studi
assess
efficaci
potenti
vaccin
found
sarscov
igg
detect
patient
month
onset
diseas
although
igm
iga
seroposit
lost
individu
longitudin
studi
need
defin
sarscov
antibodi
persist
data
differ
antigen
prepar
method
march
guest
http
cviasmorg
whole
viru
infectedcel
lysat
recombin
antigen
elisa
format
rel
diagnost
valu
time
appear
persist
differ
antibodi
type
presenc
antibodi
bodi
fluid
influenc
steroid
therapi
valu
rapid
sarscov
antibodi
detect
system
remain
incomplet
